Analysts expect Can-Fite BioPharma Ltd. to report revenue of 0.00 for 2026, against a range of 0.00 to 0.00. The most recent reported year, 2025, came in at 405,000.00, a 115.0% beat against the 188,341.77 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 853,000.00 | 810,000.00 | 743,000.00 | 674,000.00 | 405,000.00 | - | - | ||
| High Estimate | 871,273.78 | 1.24 M | 695,514.73 | 0.00 | 206,102.78 | 0.00 | 2.85 M | ||
| Low Estimate | 721,210.78 | 1.14 M | 644,661.73 | 0.00 | 170,580.76 | 0.00 | 2.66 M | ||
| Consensus Estimate | 796,242.28 | 1.19 M | 670,088.23 | 0.00 | 188,341.77 | 0.00 | 2.75 M |
Analysts expect Can-Fite BioPharma Ltd. to report earnings per share of -0.63 for 2026, against a range of -0.69 to -0.57. The most recent reported year, 2025, came in at -5.97 , in line with the -0.49 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -6.00 | -60.00 | -60.00 | -10.59 | -5.97 | - | - | ||
| High Estimate | -95.76 | -63.51 | -25.65 | -23.71 | -0.45 | -0.57 | -0.24 | ||
| Low Estimate | -112.64 | -72.09 | -31.25 | -27.31 | -0.53 | -0.69 | -0.28 | ||
| Consensus Estimate | -104.20 | -67.80 | -28.45 | -25.51 | -0.49 | -0.63 | -0.26 |
Pull Wall Street consensus for Can-Fite BioPharma Ltd. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=CANF&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "CANF", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=CANF&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();